

NAME	CTS AFFILIATION	DISCLOSURE	UPDATED
Darcy Marciniuk	COPD Committee (Chair) <u>and</u> Canadian Respiratory Guidelines Committee (CRGC) <u>and</u> Canadian COPD Alliance	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Consultant Fee, Speaker's Bureau, Advisory Committee:</b> AstraZeneca, Boehringer-Ingelheim, Canadian Agency for Drugs and Technologies in Health, GlaxoSmithKline, Health Canada, Health Quality Council of Saskatchewan, Novartis, Nycomed, Pfizer, Prince Albert Grand Council Chronic Disease Network, Saskatoon Health Region</li> <li>▪ <b>Fiduciary Position</b> (other than CTS or CRHP): American College of Chest Physicians, Chest Foundation, Lung Association of Saskatchewan</li> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Boehringer-Ingelheim, Canadian Institutes of Health Research, GlaxoSmithKline, Lung Association of Saskatchewan, Novartis, Pfizer, Public Health Agency of Canada, Royal University Hospital Foundation, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering-Plough</li> </ul>	May 3 <sup>rd</sup> , 2010
Darlene Reid	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	May 3 <sup>rd</sup> , 2010
David Todd	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Ontario Thoracic Society</li> </ul>	April 29 <sup>th</sup> , 2010
Denis O'Donnell	COPD Committee (Executive) <u>and</u> President of the Canadian Thoracic Society	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Consulting Fees and Speaker Bureau/Honoraria:</b> Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline</li> <li>▪ <b>Research/Program Grant Funding:</b> Boehringer-Ingelheim, Canadian Institutes of Health Research, Canadian Thoracic Society, GlaxoSmithKline, Merck Frosst, Novartis, Pfizer, Spear Foundation</li> </ul>	February 11 <sup>th</sup> , 2010

Dina Brooks	COPD Committee <u>and</u> Canadian COPD Alliance <u>and</u> CRC Planning Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	April 29 <sup>th</sup> , 2010
Francois Maltais	COPD Committee (Executive)	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> Boehringer-Ingelheim, GlaxoSmithKline</li> <li>▪ <b>Research/Program Grant Funding:</b> Altana Pharma, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst , Novartis, Nycomed</li> <li>▪ <b>Research Chair in COPD:</b> Canadian Institutes of Health Research/GlaxoSmithKline</li> <li>▪ <b>Speaker:</b> Boehringer-Ingelheim, GlaxoSmithKline, Pfizer</li> </ul>	June 9 <sup>th</sup> , 2010
Gail Dechman	COPD Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Research/Program Grant Funding:</b> Dalhousie University, Lung Association of Nova Scotia, Nova Scotia Health Research Foundation, Social Sciences and Humanities Research Council</li> <li>▪ <b>Membership</b> (other than CTS or CRHP): ATS, AACVPR, Canadian Physiotherapy Association, Nova Scotia College of Physiotherapy, Nova Scotia Physiotherapy Association</li> </ul>	May 12 <sup>th</sup> , 2010
Gordon Ford	COPD Committee (Executive)	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Honoraria:</b> Abbott, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer, Janssen-Ortho Inc.</li> <li>▪ <b>Appointment:</b> Medical staff, Alberta Health Services</li> <li>▪ <b>Research/Program Grant Funding:</b> Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer</li> </ul>	July 21 <sup>st</sup> , 2010
Meyer Balter	COPD Committee (Executive) <u>and</u> Canadian	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).	May 4 <sup>th</sup> , 2010

	Respiratory Guidelines Committee (CRGC)	<ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer</li> <li>▪ <b>Speaker:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Nycomed, Pfizer</li> </ul>	
Michael Stickland	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Appointment:</b> Co-director of the Centre for Lung Health, Covenant Health, Edmonton, Alberta</li> <li>▪ <b>Research/Program Grant Funding:</b> GlaxoSmithKline, Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, Alberta Lung Association</li> <li>▪ <b>Speaker:</b> GlaxoSmithKline</li> </ul>	May 9 <sup>th</sup> , 2010
Paul Hernandez	COPD Committee (Executive) <u>and</u> Canadian Respiratory Guidelines Committee (CRGC) <u>and</u> Pulmonary Vascular Disease Committee <u>and</u> Canadian COPD Alliance	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Consultant:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Lilly, Novartis, Nycomed, Pfizer</li> <li>▪ <b>CME Development and Speaker:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Medical Advisory Board:</b> Lung Association of Nova Scotia</li> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Lilly, Novartis, Nycomed, Pfizer, ZLB Behring</li> <li>▪ <b>Reviewer and Consultant:</b> Canadian Agency for Drugs and Technologies in Health</li> </ul>	April 29 <sup>th</sup> , 2010
Richard Debigare	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	April 29 <sup>th</sup> , 2010
Scott Butcher	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	April 29 <sup>th</sup> , 2010
Shannon Walker	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a</p>	April 28 <sup>th</sup> , 2010

	<u>and</u> Membership	<p>commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, GlaxoSmithKline, Nycomed</li> <li>▪ <b>Appointments:</b> On-call services, Flame Oxygen, ICU Director, Cardiopulmonary Wellness Center at InterHealth (BC)</li> <li>▪ <b>Consultant:</b> Boehringer-Ingelheim</li> <li>▪ <b>Speaker:</b> AstraZeneca, BC College of Family Physicians, BC College of Respiratory Therapists, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer</li> </ul>	
Shawn Aaron	COPD Committee (Executive)	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline</li> <li>▪ <b>Consultant:</b> Health Canada Therapeutic Products Directorate, Ontario Ministry of Health and Long Term Care</li> </ul>	May 13 <sup>th</sup> , 2010
Veronique Pepin	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Speaker:</b> GlaxoSmithKline</li> <li>▪ <b>Research/Program Grant Funding:</b> GlaxoSmithKline, Canadian Institutes of Health Research, Canadian Lung Association, Fonds de la recherche en santé du Québec,</li> <li>▪ <b>Reviewer:</b> Fonds de la recherche en santé du Québec</li> </ul>	May 2 <sup>nd</sup> , 2010
William Sheel	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	May 4 <sup>th</sup> , 2010
Donna Bleakney	External Reviewer	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	May 12 <sup>th</sup> , 2010